A market-wide longitudinal patient database creates great potential for driving business value for a specialty drug manufacturer. It can support a deep understanding of patients, their holistic situations and their treatment histories. It can enable laser-focused strategy and program development. It can create the ability to predict who will be future patients of specific therapies, […]Read Full Article
Welcome to the Blue Fin Group Information Library. Our consultants regularly publish white papers, case studies and articles, lead workshops, deliver speaking engagements, and share opinions on topics of interest to decision makers in the healthcare industry.
You don’t become an industry leader without having alot to say—click on the video vignettes below to hear our expert’s perspectives on a range of topics.
Blue Fin Group is often sought out as an expert commentator by industry publications — featuring our latest thinking and timely insights on the issues that matter most to the healthcare industry.
Blue Fin Group keeps a lens trained on many facets of the healthcare industry, and our white papers focus on singular topics that are relevant and timely. Known for our out-of-the-box thinking, these insights provide a deeper dive or different viewpoint from what others in the industry provide.
Case studies that show the transformation from challenge to solution. Each one details the existing situation, Blue Fin Group’s unique approach, the solution deployed, and the results achieved on behalf of the client. At Blue Fin Group, we deliver Deep Knowledge. Powerful Results.
Deep knowledge, unique insights and powerful perspectives focused on the healthcare industry, provided by Blue Fin Group associates.
A recent blog post described some of the business questions that can be answered by creating a market-wide longitudinal patient database. PHI de-identification is the key enabler for market-wide longitudinal patient integrity, and this blog post will expand on this theme. We’ll look at two scenarios that can enable a market-wide longitudinal patient database. The first […]Read Full Article
I took my son to Disneyland last year. I tell everyone now that visiting Disney is like the movie Groundhog Day – you have to go for at least 2 days as you’ll always mess up the first day and you need the second day to get it right. Day 1 we were a little […]Read Full Article
The coming year is full of uncertainty for pharmaceutical manufacturers and one critical proposed change may have been overlooked. While the fate of the Affordable Care Act, and the implications of any repeal or modification have dominated most discussions, relatively little focus has been placed on the potential impact of House Speaker Paul Ryan’s intentions […]Read Full Article
Who will be my future patients? What are the signals of a patient ready for my product? Who will likely be compliant and stay on therapy? Who will not? Why will Rxs not get converted to starts? Why will patients discontinue? These questions are all fair game but they require varying degrees of patient longitudinal […]Read Full Article
Every year new, complex therapies are introduced to address diseases typically treated by physician specialties that may not be accustomed to in-office procedures, or to patients that have already been receiving more-traditional therapies to treat their disease. Naturally, manufacturers of these new therapies will likely need to provide an additional level of support for physicians […]Read Full Article
We all know that often subjective and emotional reasons have a large influence on the decision. This is particularly the case when it’s hard to differentiate between one service provider and another. Senior Principal Richard Prest gives some suggestions help ensure a successful outcome on your next RFP.Read Full Article
All of us at Blue Fin Group wish you a happy holiday season, and look forward to an exciting 2017!Read Full Article